Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450792 | 0.81 | KDM4E (0.40) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL16449778 | 0.76 | KDM4E (0.41) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL14501026 | 0.75 | KDM4E (0.44) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL5668959 | 0.72 | KDM4E (0.45) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL680376 | 0.72 | KMT2A (0.35) | KDM4ESIGMAR1KMT2A | |
| SCHEMBL10165814 | 0.71 | KDM4E (0.38) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2746283 | 0.69 | KDM4E (0.37) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL12608292 | 0.69 | KDM4E (0.43) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL5924166 | 0.68 | KDM4E (0.36) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 | |
| SCHEMBL18347974 | 0.68 | KDM4E (0.42) | KDM4EPOLBTDP1SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447136-B2 | Semisynthetic derivatives of Nystatin A1 | BLIRT S.A. (PL) | 2016-09-20 | — | — | US | disclosed |
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | BLIRT S.A. (PL) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | NPC1, NPC1L1, LSS | KDM4E 4828/4885POLB 1534/4885TDP1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.